Nexium ad campaign promises nighttime relief

Share this article:
Nexium ad campaign promises nighttime relief
Nexium ad campaign promises nighttime relief
AstraZeneca is answering OTC Prevacid with ads touting Nexium's nighttime benefits.

The Purple Pill features 30-second TV spots that take a comical look at the lengths to which acid reflux sufferers will go for a good night's sleep.

The first spot in the series, by Saatchi & Saatchi Wellness, shows a middle-aged man cranking up the head of his bed using a car jack to prevent nocturnal heartburn — and prompting the family cat to slide off with a yowl. The narrator says: “Desperate for nighttime heartburn relief? For many, Nexium helps relieve heartburn day and night.”

Print ads will launch in a few weeks, AstraZeneca said.

In November, Novartis Consumer Health launched OTC Prevacid24HR with a $200 million marketing campaign touting the drug's promise of round-the-clock coverage. Nexium must also contend with P&G's Prilosec OTC and Eisai/PriCara's prescription AcipHex, among other treatments in the heavily advertised category.

Novartis consolidated consumer advertising for Prevacid24HR into Euro RSCG Adrenaline from Deutsch late last month. The Euro RSCG shop handles several other Novartis Consumer Health gastrointestinal brands, including Maalox, Excedrin and Benefiber. Deutsch continues to handle advertising for Novartis' Exelon Patch.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...